PODD | NASDAQ
Next Earnings: Jul 27, 2026
Company Overview:
10 Year PODD Performance Metrics:
Unlock All Reports & Research Dividend Stocks.
[lev_ptables no_sale]PODD Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for PODD
Based on past 10-year performance, here are PODD growth metrics:
Share price CAGR of +16.97%
Dividend CAGR of +0%
Using PODD CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| PODD (DRIP) | PODD - No DRIP | |
|---|---|---|
| Current Price | $163.26 | $163.26 |
| Start Shares | 61.25 | 61.25 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 61.25 | 61.25 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $782.56 | $163.26 |
| Total Dividends | $0 | $0 |
| Final Value | $47,933 | $10,000 |
NOTE: Above numbers are our estimate based on PODD's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
[lev_ptables no_sale]Company Info
Insulet Corp. (PODD) had its IPO on 2007-05-15, and is trader on NASDAQ stock exchange.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
PODD website: https://www.insulet.com
